Patents by Inventor Michael David BARTBERGER

Michael David BARTBERGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AKT1 MODULATORS
    Publication number: 20260193274
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: November 7, 2023
    Publication date: July 9, 2026
    Inventors: Michael David BARTBERGER, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • Substituted pyrido[4,3-d]pyrimidines as KRAS modulators
    Patent number: 12528828
    Abstract: Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.
    Type: Grant
    Filed: January 9, 2025
    Date of Patent: January 20, 2026
    Assignee: ALTEROME THERAPEUTICS, INC.
    Inventors: Michael David Bartberger, Yi Fan, Eric Anthony Murphy, Xuefeng Zhu
  • SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS
    Publication number: 20250346610
    Abstract: Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.
    Type: Application
    Filed: July 16, 2025
    Publication date: November 13, 2025
    Inventors: Michael David BARTBERGER, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • Substituted pyrido [4,3-d]pyrimidines as KRAS modulators
    Patent number: 12466842
    Abstract: Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.
    Type: Grant
    Filed: May 20, 2025
    Date of Patent: November 11, 2025
    Assignee: ALTEROME THERAPEUTICS, INC.
    Inventors: Michael David Bartberger, Yi Fan, Eric Anthony Murphy, Xuefeng Zhu
  • SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS
    Publication number: 20250282799
    Abstract: Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.
    Type: Application
    Filed: May 20, 2025
    Publication date: September 11, 2025
    Inventors: Michael David BARTBERGER, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • KRAS MODULATORS
    Publication number: 20250179093
    Abstract: Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.
    Type: Application
    Filed: January 9, 2025
    Publication date: June 5, 2025
    Inventors: Michael David BARTBERGER, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • AKT1 MODULATORS
    Publication number: 20250092040
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: November 21, 2024
    Publication date: March 20, 2025
    Inventors: Michael David BARTBERGER, Elena V. DNEPROVSKAIA, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • AKT1 modulators
    Patent number: 12209087
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: February 28, 2024
    Date of Patent: January 28, 2025
    Assignee: ALTEROME THERAPEUTICS, INC.
    Inventors: Michael David Bartberger, Elena V. Dneprovskaia, Yi Fan, Eric Anthony Murphy, Xuefeng Zhu
  • AKT1 MODULATORS
    Publication number: 20240239797
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: February 28, 2024
    Publication date: July 18, 2024
    Inventors: Michael David BARTBERGER, Elena V. DNEPROVSKAIA, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • AKT1 modulators
    Patent number: 11999730
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: June 4, 2024
    Assignee: ALTEROME THERAPEUTICS, INC.
    Inventors: Michael David Bartberger, Elena V. Dneprovskaia, Yi Fan, Eric Anthony Murphy, Xuefeng Zhu
  • AKT1 MODULATORS
    Publication number: 20240174667
    Abstract: Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: September 26, 2023
    Publication date: May 30, 2024
    Inventors: Michael David BARTBERGER, Elena V. DNEPROVSKAIA, Yi FAN, Eric Anthony MURPHY, Xuefeng ZHU
  • BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
    Publication number: 20140155415
    Abstract: The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 4, 2012
    Publication date: June 5, 2014
    Inventors: Michael David Bartberger, Michael D. Croghan, Christopher H. Fotsch, Mark H. Norman, Lewis Dale Pennington, Andreas Reichelt, David J. St. Jean, JR., Christopher M. Tegley
  • PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20140011796
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: September 12, 2013
    Publication date: January 9, 2014
    Applicant: AMGEN INC.
    Inventors: Michael David BARTBERGER, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason Duquette, John Eksterwicz, Benjamin Fisher, Brian Matthew Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael William Gribble, Dann James Gustin, Julie Anne Heath, Xin Huang, Xianyun Jiao, Michael Johnson, Frank Kayser, David John Kopecky, Sujen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan Dante Low, Brian Stuart Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin McMinn, Julio Cesar Medina, Jeffrey Thomas Mihalic, Steven Howard Olson, Yosup Rew, Philip Marley Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Compounds that interact with glucokinase regulatory protein for the treatment of diabetes
    Patent number: 8431563
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: April 30, 2013
    Assignee: Amgen Inc.
    Inventors: Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, David Joseph St. Jean, Jr., Nuria A. Tamayo, Christopher Michael Tegley, Kevin Chao Yang
  • COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
    Publication number: 20120225854
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 23, 2011
    Publication date: September 6, 2012
    Applicant: AMGEN INC.
    Inventors: Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, David Joseph St. Jean, JR., Nuria A. Tamayo, Christopher Michael Tegley, Kevin Chao Yang
  • PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20110319378
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: June 3, 2011
    Publication date: December 29, 2011
    Applicant: AMGEN INC.
    Inventors: Michael David BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian Matthew FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael GRIBBLE, JR., Darin James GUSTIN, Julie Anne HEATH, Xin HUANG, Xianyun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, Sujen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan Dante LOW, Brian Stuart LUCAS, Zhihua MA, Lawrence McGEE, Joel McINTOSH, Dustin McMINN, Julio Cesar MEDINA, Jeffrey Thomas MIHALIC, Steven Howard Olson, Yosup REW, Philip Marley ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU